Papillary thyroid cancer medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 10: | Line 10: | ||
===Immunotherapy=== | ===Immunotherapy=== | ||
===Precision Medicine and Targeted Therapy=== | ===Precision Medicine and Targeted Therapy=== | ||
* Sorafenib<ref>Targetted therapy for thyroid cancer.Cancer.org(2015). http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-treating-targeted-therapy Accessed on November,4, 2015</ref> | |||
* Lenvatinib | |||
===Hormone Therapy=== | ===Hormone Therapy=== | ||
* Levothyroxine in a dosage of 2.5-3.5 mcg/kg/day is recommended for patients post thyroidectomy. | * Levothyroxine in a dosage of 2.5-3.5 mcg/kg/day is recommended for patients post thyroidectomy. | ||
Revision as of 21:46, 5 November 2015
|
Papillary thyroid cancer Microchapters |
|
Differentiating Papillary thyroid cancer from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Papillary thyroid cancer medical therapy On the Web |
|
American Roentgen Ray Society Images of Papillary thyroid cancer medical therapy |
|
Risk calculators and risk factors for Papillary thyroid cancer medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Overview
Patients with papillary thyroid cancer are treated with radioactive iodine therapy, immunotherapy, hormone therapy and targeted medical therapy.
Medical Therapy
Radiation Therapy
- External beam radiation therapy
- Intensity modulated radiation therapy
Immunotherapy
Precision Medicine and Targeted Therapy
- Sorafenib[1]
- Lenvatinib
Hormone Therapy
- Levothyroxine in a dosage of 2.5-3.5 mcg/kg/day is recommended for patients post thyroidectomy.
References
- ↑ Targetted therapy for thyroid cancer.Cancer.org(2015). http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer-treating-targeted-therapy Accessed on November,4, 2015